Bacterial Signaling Molecules Drive Colitis-Associated Cancer : Gastroenterology | Jun 2026

Introduction:

Chronic inflammation is the principal driver of colitis-associated cancer (CAC) in patients with long-standing ulcerative colitis (UC). Although the intestinal microbiome has long been implicated in colorectal carcinogenesis, the precise microbial mediators linking inflammation to tumor development remain incompletely understood. Quorum-sensing molecules (QSMs), bacterial communication signals that regulate microbial behavior, have emerged as potential mediators of host–microbiome interactions, but their role in CAC has not previously been defined.

Problem Statement:

Current risk stratification for CAC relies largely on clinical factors such as disease duration and inflammatory burden, while mechanistic biomarkers directly linking microbial activity to carcinogenesis remain lacking. Determining whether bacterial signaling molecules actively promote tumorigenesis could reveal novel biomarkers and therapeutic targets for cancer prevention in UC.

Summary:

This translational study investigated the role of bacterial quorum-sensing molecules in UC-associated carcinogenesis using patient samples, murine CAC models, germ-free animals, microbiome analyses, metabolomics, and organoid systems.

Investigators measured three major classes of bacterial QSMs in blood samples from patients with UC and found significantly elevated levels of short-chain N-acyl homoserine lactones (scAHLs) compared with healthy controls. Importantly, patients with active inflammation and disease duration exceeding 10 years—two major risk factors for CAC—demonstrated particularly high levels of the bacterial signaling molecule autoinducer-2.

Among the identified QSMs, C6-short-chain acyl homoserine lactone (C6-scAHL) emerged as a key candidate mediator. Administration of C6-scAHL to murine models of CAC significantly increased both tumor number and tumor size, demonstrating a direct pro-tumorigenic effect.

Notably, tumor promotion persisted even in germ-free mice, indicating that C6-scAHL can drive carcinogenesis independently of the broader microbiome. This finding suggests that bacterial communication molecules themselves function as biologically active mediators rather than merely markers of microbial dysbiosis.

Exposure to C6-scAHL also induced microbiome and metabolomic alterations resembling those observed during chronic intestinal inflammation, further linking bacterial signaling pathways with tumor-promoting microenvironments.

Mechanistic studies using murine and human colonic organoids demonstrated that C6-scAHL directly stimulated the production of proinflammatory and protumorigenic cytokines. These cytokine responses provide a plausible biological pathway through which bacterial signaling molecules enhance chronic inflammation and facilitate malignant transformation.

The study therefore identifies a previously unrecognized microbiome–host communication pathway contributing to CAC development. Rather than acting through bacterial colonization alone, microbial communities may influence carcinogenesis through diffusible signaling molecules capable of modulating host immune and epithelial responses.

Clinically, these findings are important because they identify circulating QSMs as potential biomarkers for CAC risk assessment. Elevated C6-scAHL and autoinducer-2 levels may help identify UC patients at greatest risk of malignant progression, particularly those with long-standing inflammatory disease.

Furthermore, targeting bacterial quorum-sensing pathways represents an entirely new preventive strategy for CAC. Therapeutic interventions aimed at blocking QSM production, neutralizing signaling molecules, or interrupting downstream host responses could potentially reduce cancer risk without broadly disrupting the intestinal microbiome.

Overall, this study establishes bacterial quorum-sensing molecules, particularly C6-scAHL, as active drivers of colitis-associated carcinogenesis and reveals a novel microbiome-derived signaling axis that may serve as both a biomarker and therapeutic target for cancer prevention in ulcerative colitis.